Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Non-metastatic castration-sensitive prostate cancer (nmCSPC) constitutes a transient stage of the disease. It emerges with resistance to castration (manifested by testosterone levels falling below 50 ng/mL) after androgen deprivation therapy (ADT). The absence of observable metastases in standard imaging scans characterizes this stage. Simultaneously, there is a gradual increase in prostate-specific antigen (PSA) levels, reaching a minimum of 25% higher than the lowest point (nadir) while starting with a PSA level of ≥ 1.0 ng/mL. This increase must be at least 2 ng/mL and verified by a second reading. Nevertheless, the progression of this condition into metastatic disease is a complex process that is not yet fully comprehended. Most individuals diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC) do not exhibit symptoms or experience only minor ones due to localized treatment effects. In cases where the PSA doubling time is short (< 10 months) and initial PSA levels are high, the likelihood of bone metastases is notably elevated. These metastases are subsequently linked to prostate cancer. Various imaging methods are regularly employed to determine prostate cancer extent and identify metastasis and tumor recurrence signs. The advancement from non-metastatic castration-resistant prostate cancer to metastatic disease typically involves the lymph nodes and bones. Around thirty percent of patients are anticipated to develop bone metastases within 2 years. The most frequently affected areas are the pelvis, spine, and ribs. The current strategies for treating additional hormonal therapy in non-metastatic castration-resistant prostate cancer focus on hindering androgen production or its effects. The guidelines from esteemed medical organizations, such as the NCCN and EAU, now suggest that patients with nonmetastatic castration-resistant prostate cancer and a PSA doubling time of ≤ 10 months who are at an escalated risk of disease progression should receive treatments like enzalutamide, apalutamide, or darolutamide. These treatments are administered alongside ongoing ADT to delay the onset of metastasis.

·       The annual occurrence of non-metastatic castration-resistant prostate cancer in the United States ranges between 50,000 and 60,000 cases.

Viral infections typically target either the upper or lower respiratory tract. While categorization based on the responsible virus (like influenza) is possible, a more common clinical classification revolves around the syndrome displayed (such as the common cold, bronchiolitis, croup, or pneumonia). While particular pathogens tend to exhibit distinct clinical signs (like rhinovirus being linked to common cold symptoms and RSV often causing bronchiolitis), each virus has the potential to trigger various respiratory syndromes. The severity of viral respiratory ailments varies greatly, with more severe cases being more likely in older adults and infants. Respiratory viruses are divided into three groups based on their seasonal outbreaks. Influenza virus, human coronaviruses (like OC43, HKU1, 229E, and NL63 strains), and human respiratory syncytial virus (RSV) exhibit peaks during the winter (termed winter viruses). Adenovirus, human bocavirus (HBoV), parainfluenza virus (PIV), human metapneumovirus (hMPV), and rhinovirus can be detected throughout the year (referred to as all-year viruses).

Thelansis’s “Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more